© Oxford University Press 2006.
NEWS |
Negative Data From Lung Cancer Trial May Change Practice Guidelines, Study Designs
| The first 150 words of the full text of this article appear below. |
Revised practice guidelines for early non–small-cell lung cancer (NSCLC) are due this fall from the National Comprehensive Cancer Network (NCCN), triggered by new uncertainties surrounding one of the big questions in early-stage NSCLC: Does adjuvant therapy benefit patients at stage IB?
Oncologists thought they had the answer to that question 2 years ago when preliminary results from a randomized trial showed a definite survival benefit in IB—so strong, in fact, that the trial was stopped early, and adjuvant therapy became standard of care.
But the positive findings were short-lived. As data continued to accumulate, the benefit shrank, and by last spring, the results of the trial, CALGB-9633, no longer showed a statistically significant overall survival benefit for adjuvant therapy in stage IB.
"While we do see trends that continue to favor the chemotherapy arm, there is no question that the difference is less," said principal investigator Gary Strauss, M.D., associate
Changing Clinical Practice
Designing the Next Trials
Impact of Early Closing
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Miyoshi, S. Moriyama, T. Kunitomo, and S. Nawa Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., February 1, 2009; 137(2): 429 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ramsey and J. Scoggins Commentary: Practicing on the Tip of an Information Iceberg? Evidence of Underpublication of Registered Clinical Trials in Oncology Oncologist, September 1, 2008; 13(9): 925 - 929. [Abstract] [Full Text] [PDF]
|
|